Rupert Peter B, Buerger Matthew, Girard Emily J, Frutoso Marie, Parrilla Don, Ng Kevin, Gooley Theodore, Groh Veronika, Strong Roland K
Division of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Heliyon. 2024 Mar 27;10(7):e28583. doi: 10.1016/j.heliyon.2024.e28583. eCollection 2024 Apr 15.
NKG2D and its ligands are critical regulators of protective immune responses controlling infections and cancer, defining a crucial immune signaling axis. Current therapeutic efforts targeting this axis almost exclusively aim at enhancing NKG2D-mediated effector functions. However, this axis can drive disease processes when dysregulated, in particular, driving stem-like cancer cell reprogramming and tumorigenesis through receptor/ligand self-stimulation on tumor cells. Despite complexities with its structure and biology, we developed multiple novel engineered proteins that functionally serve as axis-blocking NKG2D "decoys" and report biochemical, structural, , and evaluation of their functionality.
NKG2D及其配体是控制感染和癌症的保护性免疫反应的关键调节因子,定义了一个关键的免疫信号轴。目前针对该轴的治疗努力几乎完全旨在增强NKG2D介导的效应功能。然而,当该轴失调时,它会驱动疾病进程,特别是通过肿瘤细胞上的受体/配体自我刺激驱动干细胞样癌细胞重编程和肿瘤发生。尽管其结构和生物学存在复杂性,但我们开发了多种新型工程蛋白,其功能上作为阻断轴的NKG2D“诱饵”,并报告了它们功能的生化、结构以及评估。